NIKA PHARMACEUTICALS, INC Income Statement
NIKA|4 years of annual SEC 10-K data (FY2021-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$0
FY2024
Gross Profit
N/A
FY2024
Operating Income
-$95,792
FY2024
Net Income
-$95,792
FY2024
NIKA PHARMACEUTICALS, INC reported $0 in revenue and $95,792 in net loss for FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -447.47 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Negative shareholders equity: Liabilities exceed assets
- Accrual-heavy earnings: Net income significantly exceeds operating cash flow
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| SG&A Expense | $35.2K | $64.8K | $33.7K | $14.7K |
| Operating Income | -$95.8K | -$64.8K | -$3.2M | -$14.7K |
| Net Income | -$95.8K | -$64.8K | -$3.2M | -$14.7K |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | - |
| EPS (Diluted) | $0.00 | - | $0.00 | $0.00 |
| Shares Outstanding | 876.1M | 876.1M | 396.1M | 13.2M |